| N(%) | Model 1* | Model 2†| Model 3‡ | |||
---|---|---|---|---|---|---|---|
OR(95%CI) | P-value | OR(95%CI) | P-value | OR(95%CI) | P-value | ||
follow-up in 3 months | Â | Â | Â | Â | Â | Â | Â |
stroke recurrence | Â | Â | Â | Â | Â | Â | Â |
lower eGDR group | 117 (6.74) | Ref. | Â | Ref. | Â | Ref. | Â |
higher eGDR group | 223 (4.92) | 0.72(0.58,0.91) | < 0.01 | 0.71(0.57,0.89) | < 0.01 | 0.81(0.61,1.06) | 0.12 |
favorable functional outcome (mRs 0–2) |  |  |  |  |  |  |  |
lower eGDR group | 1524 (87.79) | Ref. | Â | Ref. | Â | Ref. | Â |
higher eGDR group | 4031 (88.89) | 1.11(0.94,1.32) | 0.22 | 1.17(0.98,1.39) | 0.08 | 1.16(0.94,1.43) | 0.16 |
excellent functional outcome (mRs 0–1) |  |  |  |  |  |  |  |
lower eGDR group | 1275 (73.44) | Ref. | Â | Ref. | Â | Ref. | Â |
higher eGDR group | 3539 (78.04) | 1.28(1.13,1.46) | < 0.01 | 1.33(1.17,1.51) | < 0.01 | 1.24(1.06,1.45) | < 0.01 |
follow-up in one year | Â | Â | Â | Â | Â | Â | Â |
stroke recurrence | Â | Â | Â | Â | Â | Â | Â |
lower eGDR group | 165 (9.5) | Ref. | Â | Ref. | Â | Ref. | Â |
higher eGDR group | 354 (7.81) | 0.81(0.68,0.98) | 0.03 | 0.80(0.67,0.96) | 0.02 | 0.91(0.73,1.14) | 0.41 |
combined vascular event | Â | Â | Â | Â | Â | Â | Â |
lower eGDR group | 167 (9.62) | Ref. | Â | Ref. | Â | Ref. | Â |
higher eGDR group | 366 (8.07) | 0.83(0.69,1.00) | 0.05 | 0.82(0.68,0.98) | 0.03 | 0.93(0.75,1.17) | 0.54 |
favorable functional outcome (mRs 0–2) |  |  |  |  |  |  |  |
lower eGDR group | 1543 (88.88) | Ref. | Â | Ref. | Â | Ref. | Â |
higher eGDR group | 4109 (90.61) | 1.21(1.01,1.44) | 0.04 | 1.30(1.08,1.56) | < 0.01 | 1.55(1.24,1.93) | < 0.01 |
excellent functional outcome (mRs 0–1) |  |  |  |  |  |  |  |
lower eGDR group | 1344 (77.42) | Ref. | Â | Ref. | Â | Ref. | Â |
higher eGDR group | 3667 (80.86) | 1.23(1.08,1.41) | < 0.01 | 1.29(1.13,1.48) | < 0.01 | 1.28(1.09,1.51) | < 0.01 |